PRIMATOM System Combines CT Scanning With Radiation Therapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 9
Volume 9
Issue 9

CONCORD, Calif-Siemens Oncology Care Systems Group has unveiled the PRIMATOM System, which combines a CT scanner with a linear accelerator for radiation therapy. The machine is currently in use at the Carol G. Simon Cancer Center at Atlantic Health System’s Morristown Memorial Hospital, New Jersey.

CONCORD, Calif—Siemens Oncology Care Systems Group has unveiled the PRIMATOM System, which combines a CT scanner with a linear accelerator for radiation therapy. The machine is currently in use at the Carol G. Simon Cancer Center at Atlantic Health System’s Morristown Memorial Hospital, New Jersey.

The PRIMATOM System consists of a Siemens CT scanner on a sliding gantry combined with a PRIMUS Linear Accelerator (see Figure). The technology provides oncologists for the first time with accurate, almost real-time diagnostic-quality images of tumors within the treatment room, the company said in a news release. “It allows the patient to remain on one table while the tumor is pinpointed and treatment is delivered,” said James Wong, MD, of Morristown.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content